APA (7th ed.) Citation

H, Q., T, W., L, D., N, Y., H, C., X, P., . . . G, Y. (2025). Pharmacokinetics, safety, and tolerability of nacubactam (OP0595) after intravenous infusion: A randomized, double-blind, placebo-controlled phase I clinical trial in healthy Chinese male subjects. Clinical and experimental medicine, 26(1), 96. https://doi.org/10.1007/s10238-025-01951-1

Chicago Style (17th ed.) Citation

H, Qiu, et al. "Pharmacokinetics, Safety, and Tolerability of Nacubactam (OP0595) After Intravenous Infusion: A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial in Healthy Chinese Male Subjects." Clinical and Experimental Medicine 26, no. 1 (2025): 96. https://doi.org/10.1007/s10238-025-01951-1.

MLA (9th ed.) Citation

H, Qiu, et al. "Pharmacokinetics, Safety, and Tolerability of Nacubactam (OP0595) After Intravenous Infusion: A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial in Healthy Chinese Male Subjects." Clinical and Experimental Medicine, vol. 26, no. 1, 2025, p. 96, https://doi.org/10.1007/s10238-025-01951-1.